G-CSF in solid tumor chemotherapy: A tailored regimen reduces febrile neutropenia, treatment delays and direct costs

Medical Science Monitor

Volumn 10, Issue 2, 2004, Pages

  Tsavaris, Nicolas ^a   Kosmas, Christos ^a   Gouveris, Panagiotis ^a   Vadlaka, Maria ^a   Dimitrakopoulos, Adonios ^a   Karadima, Dimitra ^a   Pagouni, Efterpi ^a   Panagiotakopoulos, George ^a   Tzima, Evanthia ^a   Ispoglou, Sevasti ^a   Sakelariou, Dimitrios ^a   Koufos, Christos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Febrile neutropenia; G CSF administration; Grapulocyte colony stimulating factor; Neutropenia

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COST OF ILLNESS; DISEASE SEVERITY; DRUG USE; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RISK FACTOR; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; NEUTROPHILS;

EID: 10744224716     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gabrilove JL, Jakubowski A, Scher HA I et al: Effect of granulocyte-stimulating factor on neutropenia and associated morbidity to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med, 1988; 318: 1414-22
2. Trillet-Lenoir V, Green J, Manegold C et al: Recombinant Granulocyte Colony Stimulating Factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer, 1993; 29A: 319-24
3. Kanz L, Brugger W, Mertelsmann R: Hematopoietic Growth Factors and peripheral blood stem cells as supportive agents in dose intensification. Eur J Cancer, 1993; 29A: S23-S26
4. Hartman LC, Tschetter LK, Habermann TM et al: Granulocyte colony stimulating factor in severe chemotherapy induced afebrile neutropenia. N Engl J Med, 1997; 336: 1776-80
5. Ozer H, Armitage JO, Bennett CL et al: for the American Society of Clinical Oncology Growth Factors Expert Panel. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol, 2000; 18: 3558-85
6. Hoelzer D: Haematopoietic growth factors-not whether, but when and where. N Engl J Med, 1997; 336: 1822-24
7. Ferguson JE, Dodwell DJ, Seymour AM et al: High dose intensive chemotherapy with doxorubicin and cydophosphamide for the treatment of advanced breast cancer. Br J Cancer, 1993; 67: 825-29
8. Toner GC, Shapiro JD, Laidlaw CR et al: Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. J Clin Oncol, 1998; 16: 3874-79
9. Crawford J, Ozer H, Stoller R et al: Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer (r-meHuG-CSF). N Engl J Med, 1991; 325: 164-70
10. Petengell R, Gurney H, Radford JA et al: Granulocyte colony stimulating factor to prevent dose-limiting neutropenia in Non Hodgkin's Lymphoma: a randomized controlled trial. Blood, 1992; 80: 1430-36
11. th edition New York, McGraw-Hill, 1983
12. Linch DC: Evaluation of hematopoietic growth factors: defining relevant clinical endpoints in growth factor trials. Eur J Cancer, 1994; 30A: S40-S43
13. Diehl V: Future strategy for cancer treatment using recombinant human granulocyte colony stimulating factor. Eur J Cancer, 1994; 30A: S44-S47
14. Bennett CL, Smith TJ, Weeks JC et al: Use of hematopoietic colony-stimulating factors: The American Society of Clinical Oncology survey. J Clin Oncol, 1996; 14: 2511-20
15. Chouaid C, Bassinet L, Fuhrman C et al: Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: An analysis using a Markov model. J Clin Oncol, 1998; 16: 2700-07
16. Tjan-Heijnen VCG, Biesma B, Festen J et al: Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung cancer. J Clin Oncol, 1998; 16: 2708-14
17. Kurylak A, Wysocki M, Osińska-Królak M et al: Evaluation of the effect of haematopoietic growth factors on the course of myelosuppression in children with neoplastic disease. Med Sci Monit, 1999; 5: 246-52